ASM Microbe 2019
AWG Member Company Participation at ASM Microbe 2019
Eleven AWG member companies presented data from their clinical and research programs at the American Society for Microbiology’s ASM Microbe 2019 meeting held June 20-24, 2019 in San Francisco, CA. Representatives from AWG member companies participated in 64 different presentations and oral sessions.
ASM Microbe showcases the best microbial sciences in the world and provides a one-of-a-kind forum to explore the complete spectrum of microbiology from basic science to translation and application.
Friday, June 21st
Session: S020 – New Agents Discovery Summary Session: Early New Antimicrobial Agents
Time: 8:30 a.m. – 10:30 a.m.
Location: 207/208 South
Qpex Biopharma:
9:10 a.m. – 9:30 a.m.
- Broad-spectrum Orally Bioavailable Beta-lactamase Inhibitor QPX7728
VenatoRx Pharmaceuticals:
9:50 a.m. – 10:10 a.m.
- Orally Bioavailable Beta-lactamase Inhibitor VNRX-7145
Session: P404 – CIV01 – Clinical Studies of Adult Infectious Diseases: Urinary Tract Infections
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Nabriva Therapeutics:
- FRIDAY – CIV-148 – Fosfomycin for Injection (FOS) Versus (vs) Piperacillin-Tazobactam (PIP-TAZ) for Treating Complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (AP): Further Analyses of the ZEUS Study
Iterum Therapeutics:
- FRIDAY – CIV-147 – Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Adult Women
Session: P406 – CIV01 – Clinical Studies of Adult Infectious Diseases, including Clinical Trials and Diseases caused by Bacteria, Viruses, Fungi, Prions or Parasites
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Paratek Pharmaceuticals:
- FRIDAY – CIV-155 – Analysis of Pooled Microbiological Data from Two Phase 3 Studies of Omadacycline Treatment for Acute Bacterial Skin and Skin Structure Infections
Session: P446 – CPHM03 – Diagnostic Bacteriology: UTI Testing
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Iterum Therapeutics:
- FRIDAY – CPHM-846 – Impact of Urine Analysis Methods in the Diagnosis of Uncomplicated Urinary Tract Infection
Session: P430 – AAR01 – Surveillance of Antimicrobial Resistance: Genomic Analyses, Clinical and Molecular Epidemiology
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Paratek Pharmaceuticals:
- FRIDAY – AAR-540 – In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results
Session: P435 – AAR03 – Antifungal Susceptibility Surveillance and Resistance
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Cidara Therapeutics:
- FRIDAY – AAR-687: Disk Diffusion Testing of the Novel Echinocandin Rezafungin against Candida spp.– Broth vs. Disk Correlation and Quality Control
Session: P436 – AAR03 – Novel Antifungal Agent Approaches
Time: 11:00am – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
SCYNEXIS:
- FRIDAY – AAR-696: Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-Abdominal Candidiasis Mouse Model
Session: P441 – AAR07 – Preclinical Antimicrobial Pharmacokinetics and Pharmacodynamics
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
ContraFect:
- FRIDAY – AAR-768 – Pharmacodynamic Assessment of Lysin CF-301(exebacase) in Addition to Daptomycin against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model
- FRIDAY – AAR-775 – PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
Session: P403 – CIV01 – Clinical Studies of Adult Infectious Diseases: Treatment of Drug-resistant Infections
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Iterum Therapeutics:
- FRIDAY – CIV-140 – Failure of Empiric Treatment of Uncomplicated Urinary Tract Infection (UTI) Associated with Resistant Pathogens
Session: S107 – Pharma Pipeline Update: Part I
Time: 2:30 p.m. – 3:15 p.m.
Location: AAR Track Hub (Booth 5053) – Learn – Exhibit and Poster Hall
Summit Therapeutics:
2:52 p.m. – 3:03 p.m.
VenatoRx Pharmaceuticals:
3:03 p.m. – 3:14 p.m.
Saturday, June 22nd
Session: S163 – Pharma Pipeline Updates: Part II
Time: 11:00 a.m. – 11:45 a.m.
Location: AAR Track Hub (Booth 5053) – Learn – Exhibit and Poster Hall
Entasis Therapeutics:
11:00 a.m. – 11:11 a.m.
Qpex Biopharma:
11:33 a.m. – 11:44 a.m.
Session: P508 – AAR02 – Antimicrobial Agents: Mechanisms of Resistance in Gram-Negative Bacteria
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Nabriva Therapeutics:
- SATURDAY – AAR-666 – In Vitro and In Vivo Effects of Fosfomycin Resistant Mutants on Bacterial Growth and Efficacy in the Murine UTI Model
Session: P515 – AAR09 – Pharmacological Studies of Novel Investigational Agents (Phase 2/3)
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Nabriva Therapeutics:
- SATURDAY – AAR-786 – Lefamulin Activity against Respiratory Tract Pathogens Collected in the 2017 Global SENTRY Surveillance Program
- SATURDAY – AAR-785 – Lefamulin Activity against Bacterial Pathogens Commonly Associated with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Collected in the 2017 Global SENTRY Surveillance Program
Session: P506 – AAR01 – Surveillance of Antimicrobial Resistance: Molecular Typing, Clinical and Molecular Epidemiology
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Paratek Pharmaceuticals:
- SATURDAY – AAR-608 – Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and Gram-Negative Bacteria
Session: P512 – AAR07 – Clinical Antimicrobial Pharmacokinetics and Pharmacodynamics
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Cidara Therapeutics:
- SATURDAY – AAR-736 – Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Rezafungin (RZF) for Treatment of Candida Infections
Session: P513 – AAR09 – Pharmacological Studies of Investigational Agents (Phase 2/3): Late Stage Beta-Lactamase Inhibitor Combinations
Time: 11:00 a.m. – 12:00 p.m. & 4:00 p.m. – 5:00 p.m.
Location: Exhibit and Poster Hall
Entasis Therapeutics:
- SATURDAY – AAR-753 – The Novel β-Lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse, Clinical Acinetobacter baumannii calcoaceticus Complex Isolates
Sunday, June 23rd
Session: S279 – PK/PD for My FDA Package? What Do I Need?
Time: 8:00 a.m. – 10:30 a.m.
Location: 203/204 South
Cidara Therapeutics:
9:15am – 9:30am
- 6 – Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Rezafungin (RZF) for Treatment of Candida Infections
Session: P588 – AAR08 – New Antimicrobial Agents (pre-Phase 2): Early Beta-Lactams and Beta-Lactamase Inhibitor Combinations
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
Entasis Therapeutics:
- SUNDAY – AAR-714: The Novel β-Lactamase Inhibitor ETX1317 Restores the Activity of Cefpodoxime against Drug-Resistant Enterobacteriaceae
- SUNDAY – AAR-715: Cefpodoxime-ETX1317 Susceptibility is Unaffected by Ceftazidime-Avibactam Resistance Mutations V240G, D179Y and D179Y/T243M in KPC-3 beta-Lactamase
Qpex Biopharma:
- SUNDAY – AAR-706 – Discovery of QPX7728, an Ultra-Broad-Spectrum Inhibitor of Serine and Metallo Beta-Lactamases
- SUNDAY – AAR-707 – QPX7728: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Gram-Negative Bacteria
- SUNDAY – AAR-708 – QPX7728: Biochemical Characterization of Inhibitory Activity against Serine and Metallo beta-Lactamases from Enterobacteriaceae and Acinetobacter
- SUNDAY – AAR-709 – QPX7728: In Vitro Activity in Combination with Meropenem against Carbapenem Resistant Enterobacteriaceae (CRE)
- SUNDAY – AAR-710 – QPX7728: In Vitro Activity in Combination with Oral Beta-Lactam Antibiotics against Enterobacteriaceae (ENT)
- SUNDAY – AAR-711 – In Vitro Activity of the β-Lactamase Inhibitor QPX7728 Combined with Several β-Lactams When Tested against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PA)
- SUNDAY – AAR-712 – In Vivo Activity of QPX7728 in Combination with Meropenem against Carbapenem-Resistant K. pneumoniae, A. baumannii, and P. aeruginosa
- SUNDAY – AAR-713 – Pharmacokinetics of QPX7728 Following IV Dosing in Non-Clinical Species
VenatoRx Pharmaceuticals:
- SUNDAY – AAR-719 – Rescue of Ceftibuten Activity by the Oral β-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D β-Lactamases
- SUNDAY – AAR-720 – The Orally Bioavailable Beta-Lactamase Inhibitor VNRX-7145 Restores Bactericidal Activity of Ceftibuten against Enterobacteriaceae Expressing Ambler Class A, C, and/or D Enzymes
- SUNDAY – AAR-721: In Vitro Activity of Ceftibuten in Combination with VNRX-7145 and Comparators against 1,066 UTI Isolates Non-Susceptible to Amoxicillin-Clavulanate and Levofloxacin
- SUNDAY – AAR-722 – Antimicrobial Activity of Cefepime in Combination with VNRX-5133 against a Global 2018 Surveillance Collection of Pseudomonas aeruginosa
- SUNDAY – AAR-723 – Synergy/Antagonism of Ceftibuten/VNRX-7145 in Combination with Other Commonly Used Antimicrobial Agents in Gram-Negative Aerobic Bacteria, Anaerobic Bacteria, and Yeast
- SUNDAY – AAR-724 – In Vitro Permeability and Metabolic Biotransformation of Oral Beta-Lactamase Inhibitor VNRX-7145 across Species
- SUNDAY – AAR-726 – Efficacy of Ceftibuten + VNRX-7145 a Novel Beta-Lactamase Inhibitor against ESBL E. coli Strains in a Murine UTI Model
- SUNDAY – AAR-727 – Assessment of the In Vivo Pharmacodynamic Profile of Ceftibuten (CTB)/VNRX-7145 Combination against Serine β-Lactamase-Producing Enterobacteriaceae (SBL-EB) in the Neutropenic Murine Thigh Infection Model
- SUNDAY – AAR-728 – Oral Bioavailability of Novel Beta-Lactamase Inhibitor VNRX-7145 in Rats, Dogs and Non-Human Primates
Summit Therapeutics:
- SUNDAY – AAR-758 – In Vitro Activity of SMT-571 and Comparators against Clinical Isolates and Reference Strains of Neisseria gonorrhoeae
Session: P553 – CIV01 – Clinical Studies of Adult Infectious Diseases: Pneumonia in Children and Adults
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
Nabriva Therapeutics:
- SUNDAY – CIV-177 – Efficacy of Lefamulin (LEF) versus Moxifloxacin (MOX) by Pathogen in Adults with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results from the LEAP 1 and LEAP 2 Phase 3 Clinical Trials
Session: P579 – SUNDAY – AAR Late-breakers
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
Entasis Therapeutics:
- SUNDAY-AAR-LB-14: Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection of the Novel β-lactamase Inhibitor, ETX2514, in Combination with Sulbactam against Acinetobacter baumannii-calcoaceticus Complex (ABC)
Session: P574 – HMB18 – Anti-Pathogen Strategies: Fighting Back at Pathogens
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
Cidara Therapeutics:
- SUNDAY – HMB-385 – CB-012 – A Novel Antiviral-fc Conjugate for Treatment and Prevention of Influenza Virus
Session: P583 – AAR03 – Antifungal Agents and Resistance, including New Agents
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
Cidara Therapeutics:
- SUNDAY – AAR-638: Rezafungin is Efficacious against Invasive Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Harboring the TR34/L98H Mutation
SCYNEXIS:
- SUNDAY – AAR-634 – Activity of a Novel 1,3-beta-D-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata
- SUNDAY – AAR-636 – Efficacy of Ibrexafungerp (Formerly SCY-078) in a Murine Therapeutic Model of Pneumocystis Pneumonia
Session: P586 – AAR06 – Novel Approaches: Therapies, Diagnostics and Drug Discovery: Biologics
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
ContraFect:
- SUNDAY – AAR-671 – Bacteriophage Lysin CF-301 (Exebacase) in Addition to Daptomycin in a Simulated Endocardial Vegetation (SEV) PK/PD Model
- SUNDAY – AAR-679 – CF-301 and Daptomycin Treatment of Methicillin-Resistant Staphylococcus aureus Associated Experimental Osteomyelitis
SCYNEXIS:
- SUNDAY – AAR-632 – Efficacy of Ibrexafungerp (Formerly SCY-078) in the Treatment of Candida auris Cutaneous Infection in a Guinea Pig Model
- SUNDAY – AAR-633 – Efficacy of Oral Ibrexafungerp (Formerly SCY-078) in the Treatment of Candida auris Infection in a Murine Model
- SUNDAY – AAR-635 – Preclinical Safety Evaluation of the Novel Antifungal Ibrexafungerp (formerly SCY-078) Supports Long-Term Dosing
Session: P595 – CPHM02 – Antimicrobial Susceptibility Testing: Test Performance for New Agents
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
VenatoRx Pharmaceuticals:
- SUNDAY – CPHM-860 – Impact of Variations in Susceptibility Testing Parameters on the In Vitro Activity of Ceftibuten in Combination with VNRX-7145
Session: P550 – CIV01 – Clinical Studies of Adult Infectious Diseases: Fungal Infections
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
SCYNEXIS:
- SUNDAY – CIV-166 – Interim Analysis of a Phase 3 Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (Formerly SCY-078) in Patients with Refractory or Intolerant Fungal Diseases (FURI)
Session: P587 – AAR07 – To Kill A Biofilm – Novel Therapeutic Approaches
Time: 11:00 a.m. – 1:00 p.m.
Location: Exhibit and Poster Hall
ContraFect:
- SUNDAY – AAR-695 – Lysins Exhibit Potent Bactericidal Activity, Synergy and Antibiofilm Effects against Pseudomonas aeruginosa in Human Serum and Pulmonary Surfactant
Session: S339 – Pipeline Drugs to Treat Gram-negative Infections
Time: 1:30 p.m. – 4:00 p.m.
Location: 306/307/308 South
Entasis Therapeutics:
2:00 p.m. – 2:15 p.m.
- 4 – Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection of the Novel β-lactamase Inhibitor, ETX2514, in Combination with Sulbactam against Acinetobacter baumannii-calcoaceticus Complex (ABC)
Iterum Therapeutics:
- Sulopenem: An oral Thiopenem Antibiotic for the Treatment of Infections-associated Resistant Enterobacteriaceae
Session: S358 – Tackling Drug-resistant Gonorrhea (Developed in Cooperation with GARDP)
Time: 2:30 p.m. – 3:15 p.m.
Location: AAR Track Hub (Booth 5053) – Learn – Exhibit and Poster Hall
Entasis Therapeutics:
- Novel Therapeutics Targeting Drug-Resistant Gonorrhea
Monday, June 24th
Session: S378 – Antifungals New and Near
Time: 8:30 a.m. – 11:00 a.m.
Location: 201/202 South
Cidara Therapeutics:
9:05 a.m. – 9:25 a.m.
- Rezafungin (CD-101)
Amplyx Pharmaceuticals:
10:15 a.m. – 10:35 a.m.
SCYNEXIS:
8:50 a.m. – 9:05 a.m.
- 4 – Efficacy of Ibrexafungerp (Formerly SCY-078) in a Murine Therapeutic Model of Pneumocystis Pneumonia
9:40 a.m. – 10:00 a.m.
- Ibrexafungerp (SCY-078)